C5VP001A
Cellicon® Filter Assembly with Durapore® Membrane
filtration area 0.01 m2
Synonym(s):
Cellicon® Perfusion Filter with Durapore® Membrane
Select a Size
About This Item
Quality Level
material
PET support, PVDF , polyester support
agency
meets USP Biological Reactivity Test for class VI plastics (family component materials)
sterility
sterile; γ-irradiated (level of 25-40kGy)
flow rate measuring range
10 L/min (/m2)
parameter
1 psi max. reverse press. exposure at 25 °C, 1-2.5 L process volume, 15 psi at 25 °C (max. burst pressure), 5 psi max. inlet pressure at 25 °C
filtration area
0.01 m2
membrane filtration area
0.01 m2
pore size
5 μm pore size
storage temp.
15-25°C
General description
Application
Seed Train Perfusion
Features and Benefits
Other Notes
Legal Information
Still not finding the right product?
Explore all of our products under Cellicon® Filter Assembly with Durapore® Membrane
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
This page describes the financial and operational advantages offered by the Cellicon® Cell Retention Device in an N-1 perfusion process at the 2,000 L scale in comparison to a cell retention device from another supplier.
This page describes the design attributes of the Cellicon® filter assembly for cell retention and how they simplify scale-up of intensified upstream processes.
This page summarizes several performance attributes and scalability data for Mobius® iFlex Bioreactors, single-use, stirred tank systems designed to support traditional and intensified fed-batch and perfusion cell culture applications.
Related Content
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.